# Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

> **NCT04767308** · EARLY_PHASE1 · UNKNOWN · sponsor: **Huazhong University of Science and Technology** · enrollment: 18 (estimated)

## Conditions studied

- CD5+ Relapsed/Refractory Hematopoietic Malignancies
- Chronic Lymphocytic Leukemia (CLL)
- Mantle Cell Lymphoma (MCL)
- Diffuse Large B-cell Lymphoma (DLBCL)
- Follicular Lymphoma (FL)
- Peripheral T-cell Lymphomas (PTCL)

## Interventions

- **BIOLOGICAL:** CT125A cells
- **DRUG:** Cyclophosphamide, fludarabine

## Key facts

- **NCT ID:** NCT04767308
- **Lead sponsor:** Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03
- **Primary completion:** 2023-09
- **Final completion:** 2023-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2021-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04767308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04767308, "Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04767308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*